Q2 EPS Estimate for Tango Therapeutics Increased by Analyst

Tango Therapeutics, Inc. (NASDAQ:TNGX) – Equities research analysts at Leerink Partnrs raised their Q2 2025 earnings per share estimates for Tango Therapeutics in a report issued on Monday, May 12th. Leerink Partnrs analyst A. Berens now expects that the company will post earnings per share of ($0.29) for the quarter, up from their previous estimate of ($0.36). The consensus estimate for Tango Therapeutics’ current full-year earnings is ($1.19) per share. Leerink Partnrs also issued estimates for Tango Therapeutics’ Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($1.22) EPS, FY2026 earnings at ($1.11) EPS and FY2027 earnings at ($1.80) EPS.

Tango Therapeutics (NASDAQ:TNGX) last announced its earnings results on Monday, May 12th. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.02). Tango Therapeutics had a negative return on equity of 49.64% and a negative net margin of 284.42%. The firm had revenue of $5.39 million during the quarter, compared to the consensus estimate of $6.73 million.

Separately, HC Wainwright reissued a “buy” rating and issued a $13.00 price objective on shares of Tango Therapeutics in a research note on Monday, April 14th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Tango Therapeutics currently has an average rating of “Buy” and an average price target of $12.33.

Tango Therapeutics Trading Down 8.2%

Shares of NASDAQ:TNGX opened at $1.29 on Thursday. Tango Therapeutics has a 12-month low of $1.03 and a 12-month high of $12.02. The company has a market capitalization of $138.92 million, a PE ratio of -1.09 and a beta of 1.02. The business has a 50 day moving average of $1.47 and a two-hundred day moving average of $2.61.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of TNGX. TCG Crossover Management LLC purchased a new stake in Tango Therapeutics during the fourth quarter worth $33,174,000. Boxer Capital Management LLC purchased a new stake in Tango Therapeutics during the fourth quarter worth $32,077,000. Gilead Sciences Inc. purchased a new stake in shares of Tango Therapeutics in the fourth quarter valued at $15,000,000. Farallon Capital Management LLC purchased a new stake in shares of Tango Therapeutics in the fourth quarter valued at $12,360,000. Finally, Balyasny Asset Management L.P. lifted its position in shares of Tango Therapeutics by 22.0% in the fourth quarter. Balyasny Asset Management L.P. now owns 3,279,196 shares of the company’s stock valued at $10,133,000 after acquiring an additional 592,000 shares in the last quarter. Institutional investors and hedge funds own 78.99% of the company’s stock.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.